RANDOMIZED PHASE II STUDY OF TWO ASSOCIATIONS OF RITUXIMAB AND CHEMOTHERAPY, WITH A PET-DRIVEN STRATEGY, IN PATIENTS FROM 18 TO 60 WITH DLBCL CD 20+ LYMPHOMA AND 2 OR 3 ADVERSE PROGNOSTIC FACTORS OF THE AGE-ADJUSTED IPI.

assignment_turned_inproject

Funder: Institut National du CancerProject code: INCa-DGOS-337 Call for proposal: PHRC08

Funded under: PHRC

RANDOMIZED PHASE II STUDY OF TWO ASSOCIATIONS OF RITUXIMAB AND CHEMOTHERAPY, WITH A PET-DRIVEN STRATEGY, IN PATIENTS FROM 18 TO 60 WITH DLBCL CD 20+ LYMPHOMA AND 2 OR 3 ADVERSE PROGNOSTIC FACTORS OF THE AGE-ADJUSTED IPI.

- Summary
- DMPs

Partners

Hôpital le Bocage , Groupe Hospitalier Henri Mondor - Albert Chenevier , Centre Hospitalier Régional et Universitaire de Lille , Centre Henri Becquerel , HCL , CHLS

Data Management Plans

Start a new DMP in Argos

Found an issue? Give us feedback

Select content type to embed

All Research products

arrow_drop_down

<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=inca________::adb368323a5331c28c9a07545f4f26d7&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

RANDOMIZED PHASE II STUDY OF TWO ASSOCIATIONS OF RITUXIMAB AND CHEMOTHERAPY, WITH A PET-DRIVEN STRATEGY, IN PATIENTS FROM 18 TO 60 WITH DLBCL CD 20+ LYMPHOMA AND 2 OR 3 ADVERSE PROGNOSTIC FACTORS OF THE AGE-ADJUSTED IPI.

RANDOMIZED PHASE II STUDY OF TWO ASSOCIATIONS OF RITUXIMAB AND CHEMOTHERAPY, WITH A PET-DRIVEN STRATEGY, IN PATIENTS FROM 18 TO 60 WITH DLBCL CD 20+ LYMPHOMA AND 2 OR 3 ADVERSE PROGNOSTIC FACTORS OF THE AGE-ADJUSTED IPI.

Loading